迪哲医药(688192.SH)：公司肺癌领域多项最新研究成果在2025年世界肺癌大会上公布

Core Insights - The company reported its latest research findings on two new targeted therapies for lung cancer at the 2025 World Lung Cancer Conference (WCLC) [1] Group 1: Company Developments - The company presented 11 recent studies on its self-developed lung cancer targeted drug, Shuwotai (generic name: Shuwotai tablets), and the highly selective JAK1 inhibitor, Gaoruizhe (generic name: Golixitinib capsules) in the non-small cell lung cancer (NSCLC) field [1] - The international multicenter registration clinical study "Wukong 1B" (WU-KONG1B) of Shuwotai had its latest research results reported orally at the conference [1]